MSTAR

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Monday, November 6, 2023
Modex, Appetite, Biomedical Advanced Research and Development Authority, Colon, United Kingdom, Operating cost, Epstein–Barr virus, PIN, International, SARS-CoV-2, Obesity, COVID-19 testing, SHPT, Weight loss, Growth hormone therapy, HIV, Absorption, Health, Merck, Intellectual property, BARDA, Short bowel syndrome, Poster, Oxyntomodulin, Chronic kidney disease, Development, Society, Pfizer, MSTAR, COVID-19, Glucagon, GeneDx, OXM, Public, OPKO Health, CKD, Kidney, Therapy, Patient, Nutrient, Vaccine, Pharmaceutical industry, Video game, EU

OPKO Health presented late-breaking clinical data on RAYALDEE extended-release calcifediol in a poster presentation at the American Society of Nephrology Kidney Week.

Key Points: 
  • OPKO Health presented late-breaking clinical data on RAYALDEE extended-release calcifediol in a poster presentation at the American Society of Nephrology Kidney Week.
  • Operating loss was $25.4 million in the third quarter of 2023 compared with $28.3 million in the third quarter of 2022.
  • Operating loss for the third quarter of 2023 was $64.4 million compared with an operating loss of $87.8 million for the 2022 quarter.
  • OPKO’s senior management will provide a business update, discuss third quarter financial results, provide financial guidance and answer questions during a conference call and audio webcast today beginning at 4:30 p.m. Eastern time.

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Retrieved on: 
Thursday, September 28, 2023
United States Department of Health and Human Services, DNA, Biomedical Advanced Research and Development Authority, Epstein–Barr virus, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, HHS, SARS-CoV-2, Human services, Public, Infection, COVID-19, MSTAR, Administration for Strategic Preparedness and Response, DRS, Research, Antibody, Bangladesh Technical Education Board, Modex, Messenger, Vaccine Research Center, Administration, Development, OPKO Health, Merck, BARDA, Virus, NIH, Vaccine

The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.

Key Points: 
  • The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.
  • Additional funding of up to $109 million may be available from BARDA upon achieving particular milestones to develop multispecific antibodies targeting other viral pathogens such as influenza.
  • “We are excited to partner with BARDA to advance the potential of our MSTAR multispecific antibody platform as a versatile solution to major viral threats,” said Drs.
  • Gary Nabel and Elias Zerhouni, Co-Founders of ModeX and, respectively, President, Chief Executive Officer of ModeX and President of OPKO.

Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics

Retrieved on: 
Tuesday, May 23, 2023
Antibody, Modex, HBM, MSTAR, ITM, OPKO Health, Therapy, Research, IND, Harbor, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM), today announced it has entered into an agreement with ModeX Therapeutics, an OPKO Health company, for the use of Nona's platforms to support ModeX's development of multispecific antibody therapeutics.

Key Points: 
  • CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM), today announced it has entered into an agreement with ModeX Therapeutics, an OPKO Health company, for the use of Nona's platforms to support ModeX's development of multispecific antibody therapeutics.
  • Under the terms of the agreement, ModeX will have access to Nona Bioscience's fully human Harbour Mice® platforms to accelerate discovery of monoclonal antibodies to be integrated into ModeX's MSTAR platform.
  • The collaboration aims to leverage each company's unique strengths to drive forward the discovery of cutting edge treatments.
  • "We look forward to partnering with Nona Biosciences to accelerate and enhance our discovery of novel multispecific antibody constructs that our team can advance into clinical development," said John Mascola, M.D., Chief Scientific Officer at ModeX.

Amstar Appoints New Leadership

Retrieved on: 
Thursday, July 19, 2018
Domino Foods, Zeuner, MSTAR

Jason Lucas, Amstar's current President, will step down from his role at the end of July 2018 after 12 years meaningfully contributing to Amstar, including serving as President over the last two years.

Key Points: 
  • Jason Lucas, Amstar's current President, will step down from his role at the end of July 2018 after 12 years meaningfully contributing to Amstar, including serving as President over the last two years.
  • Amstar would like to thank Jason for his efforts in positioning the company for continued success.
  • Karp and Zeuner joined Amstar within the last year where Karp oversaw U.S. acquisitions and new business initiatives and Zeuner was responsible for managing the company's international platform.
  • Lucas said: "After 12 years at Amstar and having managed the company through its last stages of transition, I am ready to embrace new opportunities.

Amstar Appoints New Leadership

Retrieved on: 
Thursday, July 19, 2018
Domino Foods, Zeuner, MSTAR

Jason Lucas, Amstar's current President, will step down from his role at the end of July 2018 after 12 years meaningfully contributing to Amstar, including serving as President over the last two years.

Key Points: 
  • Jason Lucas, Amstar's current President, will step down from his role at the end of July 2018 after 12 years meaningfully contributing to Amstar, including serving as President over the last two years.
  • Amstar would like to thank Jason for his efforts in positioning the company for continued success.
  • Karp and Zeuner joined Amstar within the last year where Karp oversaw U.S. acquisitions and new business initiatives and Zeuner was responsible for managing the company's international platform.
  • Lucas said: "After 12 years at Amstar and having managed the company through its last stages of transition, I am ready to embrace new opportunities.